Floatz logo

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE

Confusion

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Confusion cohort.

Asset / SponsorPhaseRating
PROPOFOL
RenJi Hospital
Phase 4BB
ISOFLURANE
Duke University
Phase 4BB
Suvorexant
Mayo Clinic
Phase 4BB
Clonidine
Insel Gruppe AG, University Hospital Bern
Phase 4BB
Cyclopofol
RenJi Hospital
Phase 4BB

View all 23 →

Same molecule, other indications

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE is also rated in:

major depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
major depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →